#USA #Robbins Geller #San Diego #Sarepta Therapeutics #SRPT

A Call for Action: Sarepta Therapeutics Class Action Lawsuit

The recent announcement by Robbins Geller Rudman & Dowd LLP has raised eyebrows across the financial community as it highlights a significant opportunity for investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) who may have suffered considerable financial losses. There is an impending deadline for affected investors to step forward and potentially lead a class action lawsuit against the company, stemming from troubling allegations regarding its flagship treatment, ELEVIDYS.

Understanding the Allegations

The class action lawsuit, titled Dolgicer v. Sarepta Therapeutics, Inc., has been initiated to address claims that Sarepta and certain executives violated the Securities Exchange Act of 1934. The allegations suggest that during the class period—spanning from June 22, 2023, to June 24, 2025—Sarepta made several misleading statements about the safety and efficacy of ELEVIDYS. The therapy, a gene treatment aimed at addressing Duchenne muscular dystrophy, has recently come under intense scrutiny due to serious patient safety concerns.

Key Concerns Highlighted

1. Safety Risks: The lawsuit alleges that Sarepta failed to disclose significant safety risks associated with ELEVIDYS. Investors had a right to expect transparent communication regarding the potential dangers of the drug, especially when it was revealed that some patients suffered serious adverse effects.
2. Misleading Clinical Trial Data: The complaint states that the trial regimens in place were inadequate for identifying severe side effects, putting participants at risk without proper informed consent.
3. Regulatory Scrutiny: The gravity of adverse events linked to ELEVIDYS has raised red flags with regulatory bodies, leading Sarepta to halt recruitment and dosing in key clinical trials. This decision likely has dour financial implications, impacting investor confidence and stock performance.

Recent Stock Price Volatility

The true impact of these allegations became starkly evident when Sarepta's shares experienced drastic fluctuations following crucial disclosures:

• - On March 18, 2025, after announcing a patient's death due to acute liver failure linked to ELEVIDYS, the stock plummeted over 27%.
• - Further revelations on April 4 led to another decline of over 7%, as European regulatory authorities requested a review of the troubling incident.
• - By June 15, 2025, after disclosing a second patient death, the stock suffered a staggering decline of 42%, prompting Sarepta to suspend shipments of ELEVIDYS to non-ambulatory patients.
• - Finally, a June 24 FDA announcement regarding ongoing investigations into ELEVIDYS led to yet another drop of 8% in stock price, reflecting the erosion of investor confidence.

Opportunity for Investors

Given the substantial losses during this tumultuous period, Robbins Geller is encouraging aggrieved investors to come forward. Those who purchased Sarepta securities during the specified time frame will have until August 25, 2025, to seek appointment as lead plaintiff in the class action. This is a crucial step to ensure that their voices are heard and they may potentially recover losses incurred.

The Process to Become Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 provides a pathway for investors to assume the lead plaintiff role, generally awarded to the individual with the most significant financial stake in the litigation. As a lead plaintiff, one can guide the direction of the case and select a law firm for legal representation—all while advocating on behalf of all class members.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is a renowned law firm specializing in defending investors in securities fraud cases. The firm has achieved remarkable success in securing refunds for its clients, recovering over $2.5 billion in securities-related class actions in 2024 alone. Its history underscores its capability to advocate effectively on behalf of investors.

Conclusion

For Sarepta investors facing losses, this is a critical moment to take action and consider leadership in the ongoing class action lawsuit. Engaging with competent legal representation can empower them in their quest for financial redress. Interested parties should visit the Robbins Geller website for more information and next steps. The pursuit of justice via the class action route can signal a significant turning point in the wake of troubling developments for Sarepta Therapeutics.